Results

Total Results: 1,651 records

Showing results for "described".

361. Version 2_Risk of Reinfection From SARS-CoV-2 -- An Update of an Antibody Response Following SARS-CoV-2 Infection and Implications for Immunity: A Living Rapid Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/version-2-risk-of-reinfection-from-SARSCoV2_0.pdf
     December 31, 2022 - In March 2021, we published a living rapid review that described the humoral (antibody) response after … As described below, for the remaining (included) studies, we performed a second risk of bias assessment … Some of the considerations for each of these areas are described below: • Sampling. … In the other relatively large series, a study from Austria, five cases were described as moderate and … Was followup complete, and if not, were the reasons to loss to follow up described and explored?

362. Disposition of Comments for Technical Brief 25 Disparities within Serious Mental Illness (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/mental-illness-disparities_disposition-comments.pdf
     May 26, 2016 - effectiveness of interventions and gaps in knowledge base and high priority needs for research were described

363. Liver-Cancer Research-Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/liver-cancer_research-protocol.pdf
     July 24, 2013 - in the Review The criteria for inclusion and exclusion of studies will be based on the KQs and are described … We will use the inclusion criteria described in Appendix A. … Data Synthesis We will construct evidence tables identifying the study characteristics (as described … Outcomes The strength of evidence for each KQ will be assessed by one researcher for each outcome described … in the PICOTS using the approach described in the AHRQ Methods Guide for Effectiveness and Comparative

364. Evidence-based Practice Center Systematic Review Protocol (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/venous-ulcers-treatment_research-protocol.pdf
     September 13, 2012 - www.effectivehealthcare.ahrq.gov Published Online: September 13, 2012 as moisturizers o At least moderate compression described … • At least moderate compression described either qualitatively or quantitatively (>20 mm), so that … • At least moderate compression described either qualitatively or quantitatively (>20 mm), so that … study (a) included at least 30 patients with chronic venous leg ulcers for at least 6 weeks; (b) described … dressings containing non-active components such as moisturizers o At least moderate compression described

365. Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/topic-nomination-bone-metastases.pdf
     February 01, 2017 - bonemetastases should be considered for retreatment while adhering to normal tissue dosing constraints described … treatment should be considered for EBRT retreatment while adhering to normal tissue dosing constraints described … metastases should be considered for retreatment while adhering to normal tissue dosing constraints described … treatment should be considered for EBRT retreatmentwhile adhering to normal tissue dosing constraints described … Practitioners should closely adhere to quality and safety considerations for SBRT delivery as described

366. Mental-Illness-Adults-Prisons Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/mental-illness-adults-prisons_executive.pdf
     August 01, 2013 - Our methods for judging risk of bias of individual studies are described above; we took the median … systematic reviews have been conducted on interventions for offenders with SMI; however, neither review described … Balanced Reporting of All Interventions Assessed The trials that addressed KQ1 described the treatment … The trials that addressed KQ2 described the treatment of interest in detail but provided very little … However, this conclusion is based on two trials that poorly described both the treatment and its comparator

367. Disposition of Comments Report for Procalcitonin-Guides Antibiotic Therapy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer78_procalcitonin_disposition_20121210.pdf
     October 05, 2012 - PR (#2) Introduction Introduction: The relevant issues are well described in the introduction. … As described in the report and detailed in the abstraction tables, 16 of the 18 RCT's were truly using … The separation of proximal, process measures and distal clinical outcomes is clearly described and … Commentator & Affiliation Section Comment Response PR (#3) Methods Data synthesis: the paragraph described … response necessary PR (#6) Discussion Conclusion Pages 63 - 66: While the research gaps enumerated, described

368. final Fibromyalgia CER protocol_3-31-14 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/fibromyalgia_research-protocol.pdf
     April 03, 2014 - based on the PICOTS framework outlined in Section II above, and the study-specific inclusion criteria described … of the individual RCTs that comprise each pooled analysis will be assessed per the Cochrane tool as described … 2010), narrow inclusion criteria or patient and intervention characteristics different than those described … Yes Intervention sufficiently described Partially Some of the above features. … No Intervention poorly described 6. Is the selection of the comparison group appropriate?

369. Automated-Entry Patient Generated Health Data for Chronic Conditions: The Evidence on Health Outcomes (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/patient-generated-health-data-protocol-chronic-conditions.pdf
     March 17, 2020 - For consistency between reports, we will use the same risk-of-bias assessment tool described in the … freely available and for which the accumulated published evidence indicates effectiveness or harm (as described … available and for which the accumulated published evidence indicates effectiveness or harm (as described

370. serious-mental-illness-outcomes-140303 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/mental-illness-outcomes_research-protocol.pdf
     March 03, 2014 - In 2006, the Institute of Medicine (IOM) described an approach for developing, testing, and validating

371. Disposition of Comments Report for Strategies To Reduce Cesarean Birth in Low-Risk Women (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cesarean-birth-2010_disposition-comments.pdf
     January 01, 2010 - We included only those studies that met the inclusion criteria described in methods. … For example, rather that "periodic increases" being described as normal, it might be better to state … The characteristics of the studies are sufficiently described and key messages conveyed. … Too much of the studies was described under the subheading, then two paragraphs down went into the … Yes, the target population, audience, and key questions were described explicitly.

372. Future Research Needs for Treatment of Obstructive Sleep Apnea (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/sleep-apnea-treatment-future_research.pdf
     February 01, 2012 - These modifications are described in the first part of the Results section. … These dimensions and the Effective Health Care Program guidance on them were described in detail in … For each topic, we described our assumptions about the most appropriate PICOD criteria, in particular … These considerations are described as follows: • Use established metrics to measure compliance. … The patient advocates on the stakeholder panel described a demand by patients for better training,

373. Trauma Informed Care: A Systematic Review (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/trauma-informed-care-executive-summary.pdf
     January 01, 2025 - Our findings of insufficient evidence do not mean that none of the individual interventions described

374. Outcome Definition and Measurement in Observational Comparative Effectiveness Research
     effectivehealthcare.ahrq.gov/sites/default/files/outcome-definition-and-measurement-chapter-6.pptx
     January 01, 2013 - considered when developing outcome definitions for observational comparative effectiveness research studies, described … considered when developing outcome definitions for observational comparative effectiveness research studies, described … considered when developing outcome definitions for observational comparative effectiveness research studies, described

375. Intermittent Inhalded Corticosteroids and Long-Acting Muscarinic Antagonists for Asthma (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-194-evidence-summary-corticosteroids-asthma.pdf
     October 01, 2017 - maintenance treatment of asthma in patients 6 years and older.4 The review focuses on drugs as a class, as described

376. Disposition of Comments for Evidence Report 224 Omega-3 Fatty Acids (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/omega-3-maternity_disposition-comments.pdf
     October 12, 2016 - We mentioned in our list of study limitations that many interventions described as n-3 FA (especially … In my opinion details and characteristics are more than sufficient, and very clearly described, once … The Gustafson study was described narratively in the section on cognitive outcomes, although one domain … TEP Reviewer #4 Results In general results present enough detail and studies are clearly described … TEP Reviewer #4 Discussion/Conclusion Limitations are well described and implications of the major

377. Disposition of Comments_Systematic Review: Implementing Recommended Mental Health and Substance Use Screening and Counseling Interventions in Primary Care Settings for in Children and Adolescents (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/behavioral-health-screening-disposition-comments.pdf
     April 09, 2025 - Concerns about this are further described below. … TEP Reviewer 1 Discussion As described above, there may be important lessons that are missed because … We described our approach to doing this in the paragraph that starts on page 33, line 34. … the ERIC/EPOC taxonomies that were utilized to classify the implementation strategies that were described … Clinical practice implications and limitations are well described. Thank you for your comment.

378. Breast-Cancer-Imaging Technical-Brief (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/breast-cancer-imaging_technical-brief.pdf
     October 01, 2014 - We found three published studies that described use of bone scans to evaluate treatment of metastatic … We identified four published studies9,15,16,20 that described use of MRI to evaluate treatment of metastatic … use of FDG,10,11,14-17,20,21,23,24 four described FLT,12,13,18,22 one described F-FMISO,11 and two … described FES19,20 (two studies evaluated more than one kind of tracer). … PET scans conducted 1990-1994 using tracer MET, now obsolete (1) Described diagnostic breast imaging

379. Disposition of Comments for Efficacy and Safety of Screening for Postpartum Depression (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/depression-postpartum-screening_disposition-comments.pdf
     May 01, 2013 - However, the Two- Question screen is not mentioned/described immediately before or after Table A. … Peer Reviewer 1 Results Yes, the studies are described with clarity and enough detail. … TEP Member 2 Results The studies were described well for the intevention- --impact of screening but less … They were well described for the "setting" quesiton. … The methodology is clearly described and of the highest quality.

380. Disposition of Comments for Quality Improvement Interventions To Address Health Disparities (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/disparities-quality-improvement_disposition-comments.pdf
     August 27, 2012 - Perhaps in sections within the ES and the Full Report where disparities indicators are described. … We have removed the names of the RCTs; they are described in the Full Report. … TEP #2 Methods Conditions: same problems as described for Executive Summary. … TEP #3 Discussion/ Conclusion The limitations are described adequately. … We have ordered the interventions as described above.